CMPS earnings

Compass management will host a conference call at 8:00 am ET (1:00 pm UK)  Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NA

Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/698442687. The webcast will be archived for 30 days. About Compass Pathways Compass Pathw

Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:

Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: F

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30% Cash position of $207 million Conference call October 31 at 8:00 am ET (12:00 pm UK) Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progres

Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024. The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: Third Quarter 2024 Financial Results The webcast will also be avai

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2024 and an update on recent business progress. "As we continue to

LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, and provide an update on recent business developments, on August 1, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on August 1, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2024 Financial Res

COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8 at 8:00 am ET (1:00 pm UK) LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-ba

LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2024 ending March 31, 2024, and provide an update on recent business developments, on May 8, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2024 Financial Res

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025Teri Loxam to assume Chief Financial Officer role on March 1, 2024Cash position of $220.2 million at December 31, 2023, additional $31.4 million net cash raised to date in first quarter 2024Conference call February 29 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided

LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2023 ending December 31, 2023, and provide an update on recent business developments, on February 29, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on February 29, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: Fourth Qua

Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sitesSecured up to $285 million private placement financing with $125 million upfrontCash position at September 30, 2023 of $248.0 millionConference call on November 2 at 8:00 am ET (12:00 pm UK) LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2023 and provided an update on recent progress across its business. Kabir Nath, Chief Executive Officer, said, "We continue to make progress in our COMP36

LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2, 2023. The management team will host a conference call at 8:00 am ET (12:00 pm UK) on November 2, 2023. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the COMPASS Pathways website at: Third Quarter 2023 Financial Results The webcast w

LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program ongoing and on trackCPT® III code for in-person psychedelic therapy support accepted by the American Medical AssociationCash position at June 30, 2023 of $148.2 millionTerm loan facility up to $50 million securedConference call today at 8:00 am ET (1:00 pm UK) COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the second quarter 2023 and gave an update on recent progress across its business. Kabir Nath, Chief Executive Officer, said, "This has been another quar

LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2023, and provide an update on recent business developments on August 3, 2023. The management team will host a conference call at 8:00 am ET (1:00pm UK) on August 3, 2023. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on COMPASS Pathway's website at: Second Quarter 2023 Financial Results The webcast will als

 LONDON, May 11, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program underway, patients have been treated in both trialsCPT® III code for in-person psychedelic therapy support accepted by the American Medical AssociationCash position at 31 March 2023 of $117.1 million, additional $26.9 million net cash raised through ATM facility to date in the second quarterConference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the first quarter 2023 and gave an update on recent progress across its

LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2023, and provide an update on recent business developments on 11 May 2023. The management team will host a conference call at 8:00am ET (1:00pm UK) on 11 May 2023. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on COMPASS Pathway's website at: First Quarter 2023 Financial Results T

Highlights: Phase 3 pivotal program underway - important updates announcedPhase 3 long term follow up definedCash position at 31 December 2022 of $143.2 millionConference call today at 8:00am ET (1:00pm UK) LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business. Kabir Nath, Chief Executive Officer, said, "During this past quarter, we commenced our COMP360 phase 3 pivotal program in treatment-resistant dep

LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2022, and provide an update on recent business developments on 28 February 2023. The management team will host a conference call at 8:00am ET (1:00pm UK) on 28 February. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on COMPASS Pathway's website at: Fourth Quarter 2022 Financial R

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Highlights: Phase 3 pivotal program design finalized and on track to start in 2022; several clinical sites have been initiatedPhase 2b trial data published in The New England Journal of MedicineCash position at 30 September 2022 of $173.1 millionConference call today at 8:00am ET (12:00pm UK) COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2022 and gave an update on recent progress across its business. George Goldsmith, Executive Chairman of COMPASS Pathways, said, "

LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 November 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 3 November. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on COMPASS Pathway's website at: Third Quarter 2022 Financial Results. The webcast wi

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer       Phase III program submitted to FDA and under reviewCOMP360 phase II study in anorexia nervosa launchedCash position at 30 June 2022 of $207.2 millionConference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business. George Goldsmith, Executive Chairman of COMPASS Pathways, said, "Our dec

LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2022, and provide an update on recent business developments on 4 August 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 4 August. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on COMPASS Pathway's website at: Second Quarter 2022 Financial Results. The webcast will

LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Highlights: End of phase II meeting held with FDAAward of Innovation Passport as part of the UK MHRA Innovative Licensing and Access Pathway ILAPFinalising phase III in TRD program design to be ready for second half of 2022Pioneering collaboration with King's College London and South London and Maudsley NHS Foundation Trust, to create The Centre for Mental Health Research and Innovation in the UKCash position at 31 March 2022 of $243.7 millionConference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access t

LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2022, and provide an update on recent business developments on 10 May 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 10 May. The call can be accessed by dialing (800) 926-7358 from the United States, +1 (212) 231-2914 internationally, and 0800 496 0823 from the UK, followed by the conference ID: 22018578. The call will also be webcast on the Investors section of the COMPASS Pathways webs

LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological supportPositive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRDLaunch of phase II study of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD)New senior executives appointed: Dr Guy Goodwin as Chief Medical Officer, Mike Falvey as Chief Financial Officer, and Matt Owens as General Counsel and Chief Legal OfficerWell capitalise

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 24 February. The call can be accessed by dialing (833) 665-0659 from the United States, (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 2825279. The call will also be webcast on the Investor

Highlights: Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological supportLaunch of phase II study of COMP360 psilocybin therapy for PTSDPositive signals from Maryland Oncology Hematology open-label investigator initiated study of COMP360 psilocybin therapy for depression in cancerAcquisition of IP portfolio of novel psychedelic compounds and prodrugsHamilton Morris appointed full-time consultantNew US composition patent granted for crystalline psilocybinConference call today at 1:00pm UK (8:00am ET) LONDON, Nov. 09, 2021 (GL

Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support COMPASS management team to host an investor conference call today at 1.00pm UK (8.00am ET) London, UK – 9 November 2021             COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that its groundbreaking phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression has achieved its primary endpoint for the high

London, U.K., Nov. 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2021, and provide an update on recent business developments, on 9 November 2021. The management team will host a conference call at 1:00pm UK (8.00am ET) on 9 November. The call can be accessed by dialing (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 34908054. The call will also be webcast on the Investors section of the CO

London, UK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2021, and provide an update on recent business developments, on 11 August 2021. The management team will host a conference call at 1:00pm UK (8.00am ET) on 11 August. The call can be accessed by dialing (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 3495828. The call will also be webcast on the Investors section of the COMPASS Pa

Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021First Centre of Excellence, a research facility and innovation lab, established at Sheppard Pratt (Baltimore, Maryland, US)Discovery Center expanded into network of world-leading scientists developing new optimised psychedelic compoundsConference call today at 1.00pm GMT (8.00am ET) LONDON, March 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2020 and